Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Sea Limited — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Sea Limited trades at $94 (market cap $58.76B). The key difference: Sea Limited is far larger — about 60.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Sea Limited for 103 Days on average.
| MRVI | SE | |
|---|---|---|
Market Cap | $972.90M | $58.76B |
Volume | 4,325,710 | 5,236,560 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.00 | $165.70 |
52-Week Low | $2.83 | $78.16 |
Typical Hold Time | 0 Days | 103 Days |
Enterprise Value | $1.08B | $53.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Sea Limited (SE) trades at $95.31, down 0.59% with a bearish technical signal. The company shows strong revenue growth from $22.94B in 2025 to projected $27.7B in 2026, with net income reaching $1.58B. Recent earnings show mixed results with Q4 2025 missing estimates but Q1 and Q2 2026 beating expectations. Analyst consensus remains strongly bullish with 72.7% buy ratings and a $153.67 price target, representing 61% upside potential from current levels.
The investment case hinges on continued e-commerce and fintech growth despite recent stock weakness. Key risks include margin compression concerns and insider selling activity. Positive cash flow generation since 2025 and improving profitability metrics support the bullish analyst outlook, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
